Actavis Inc (ACT)
135.78USD
1 Aug 2013
$1.51 (+1.12%)
$134.27
$134.76
$136.12
$134.60
1,037,765
1,679,274
$136.29
$73.39
About
Overall
| Beta: | 0.36 |
| Market Cap (Mil.): | $17,878.37 |
| Shares Outstanding (Mil.): | 133.15 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ACT | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 37.93 | 37.76 |
| EPS (TTM): | -4.25 | -- | -- |
| ROI: | -6.96 | 19.48 | 18.76 |
| ROE: | -15.86 | 20.17 | 19.59 |
Warner Chilcott markets $4.4 billion deal
NEW YORK - Specialty pharmaceutical Warner Chilcott Plc is in market with $4.4 billion in credit facilities that will refinance and combine debt following the company's acquisition by drug manufacturer Actavis Inc , sources told Thomson Reuters LPC.
RLPC: Warner Chilcott markets $4.4B deal
NEW YORK, July 3 - Specialty pharmaceutical Warner Chilcott Plc is in market with $4.4 billion in credit facilities that will refinance and combine debt following the company's acquisition by drug manufacturer Actavis Inc, sources told Thomson Reuters LPC.
U.S. justices say FTC can challenge deals to keep generic drugs off market
WASHINGTON, June 17 - The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals that brand-name drug companies make with generic rivals to keep cheaper products off the market.
PRESS DIGEST - Financial Times - May 21
Essar Oil to sign fuel-for-cash deal with China Development Bank
Actavis to buy Warner Chilcott in $5 billion stock deal
- Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.
UPDATE 4-Actavis to buy Warner Chilcott in $5 billion stock deal
May 20 - Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.
CORRECTED-UPDATE 1-Actavis to buy Warner Chilcott in $5 billion stock deal
(Corrects to show deal value of $5 billion, not $8.5 billion)
US STOCKS-Futures little changed after records, acquisitions eyed
* Actavis to acquire Warner Chilcott in stock-for-stock deal
Actavis to buy Warner Chilcott in $8.5 bln deal
May 20 - Generic drugmaker Actavis Inc will buy specialty pharmaceuticals company Warner Chilcott Plc in a stock deal valued at about $8.5 billion.
BRIEF-Actavis says to buy Warner Chilcott for $8.5 bln
May 20 - Actavis Inc : * Recommended offer for Warner Chilcott by Actavis * Will acquire Warner Chilcott Plc in a stock-for-stock transaction valued at
Competitors
| Price | Change | |
|---|---|---|
| McKesson Corporation (MCK.N) | $123.51 | +0.85 |
| Cardinal Health Inc (CAH.N) | $51.09 | +1.00 |
| AmerisourceBergen Corp. (ABC.N) | $58.80 | +0.53 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
| Mylan Inc. (MYL.OQ) | $33.99 | +0.43 |

Estimates